Anupam Rasayan India Q1 FY27 results (Apr–Jun 2026) and concall

Chemicals · Concall AI · Call held 14 Aug 2026

Company page: Anupam Rasayan India share price, financials & guidance record

Anupam Rasayan India Limited reported a strong start to FY27 with consolidated total income growing 36% year-on-year, driven by new product commercialization and robust demand. The company achieved a global first by commercializing ETFA using flow chemistry and saw significant contributions from the Jayhawk acquisition. While EBITDA margins remained healthy, PAT growth was tempered by higher depreciation. The acquisition of Bliss GVS Pharma is on track, further strengthening the company's integrated pharmaceutical platform.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 34.8%, net profit up 6.3% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	294	390	500	486	731 +149%	512 +31%	636 +27%	655 +35%
Expenses	214	266	356	362	596	385	498	493
EBITDA	80	124	144	124	136 +70%	127 +2%	137 −5%	162 +31%
Margin	27%	32%	29%	26%	19%	25%	22%	25%
Other income	2	-4	6	5	8	2	3	13
Interest	27	32	31	36	36	35	42	49
Depreciation	22	29	31	31	32	34	43	56
Profit before tax	34	59	88	63	76 +124%	60 +2%	56 −36%	70 +11%
Tax rate	10%	9%	29%	23%	24%	-1%	0%	27%
Net profit	31	54	63	48	57 +84%	61 +13%	56 −11%	51 +6%
EPS	1.52	2.56	4.05	3.10	3.90	4.31	3.75	3.39

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Chemicals earnings calls